			
CERTIFICATE OF TH	RANSMISSION BY FA	ACSIMILE (37 CFR 1.8)	Docket No.
Applicant(s): Mansoor Sar			UCT-0046-P2
Serial No.	Filing Date	Examiner	Group Art Unit
10/609,133	June 26, 2003	NYA	NYA
Invention: OPTINEURIN	AND GLUACOMA		RECEIVED CENTRAL FAX CENTER
			MAY 2 & 2004
	Amond Trong I Lette	an (1 mg) & Brolleninger, Amand (5 acc)	OFFICIAL
I hereby certify that this	Amend, Trans.i Lette	er (1 pg) & Preliminary Amend. (5 pgs) (Identify type of correspondence)	Eximples (5. / pgs)
is being facsimile transmitte	ed to the United States Pa	tent and Trademark Office (Fax. No.	703-872-9306
on May 24, 200	14		
(Date)			
		Lindsay Wells	·
		(Typed or Printed Name of Person Sig	ning Certificate)
	·		
	· · · · · · · · · · · · · · · · · · ·	(Signature)	
	Note: Each paper mus	st have its own certificate of mailing.	
			1

AMENDMENT TRANSMITTAL LETTER (Small Entity) Applicant(s): Mansoor Sarfarazi et al.					Docket No. UCT-0046-P2	
Serial No. Filing Date 10/609,133 June 26, 2003		Examiner NYA		Group Art Unit		
Invention: OPTINEURIN AND GLAUCOMA						
		THE COMMISS	ONER FOR PATENTS:			
Transmitted herewith is an amendment in the above-identified application. Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. A verified statement to establish Small Entity status under 37 CFR 1.27 is enclosed. The fee has been calculated and is transmitted as shown below.						
		CLAIMS A	S AMENDED			
	CLAIMS REMAINING	HIGHEST#	NUMBER EXTRA	RATE	ADDITIONAL	
	AFTER AMENDMENT	PREV. PAID FOR			FEE	
TOTAL CLAIMS	43 -	43 =		x \$9.		
INDEP. CLAIMS	9 -	9 =	0	x \$43		
Multiple Depender	nt Claims (check if appl				\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00						
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 06-1130 ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. Karry Q. Jewy Dated: May 24, 2004 Signature						
Karen A. LeCuyer Ph.D. Registration No. 51,928 Customer No. 23413 (860) 286-2929 Customer No. 23413 Custome						
1 60.			Typed or Printed	Typed or Printed Name of Person Mailing Correspondence		

Docket No. UCT-0046-P2

RECEIVED CENTRAL FAX CENTER MAY 2 4-2004

IN THE UNITED	STATES	PATENT	AND T	RADEMARK	OFFICE
---------------	---------------	--------	-------	----------	--------

OFFICIAL

Applicant:	Sarfarzi et al.)	Group Art Unit:
Serial No.:	10/609,133		
Filed:	June 26, 2003	,)	Examiner:
For:	OPTINEURIN AND GLAUCOMA))	

PRELIMINARY AMENDMENT

Box Non-Fee Amendment Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to substantive examination of the above-referenced application, please enter the following amendments.